PMID: 9194767Jun 1, 1997Paper

Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats

Arteriosclerosis, Thrombosis, and Vascular Biology
A BenetosM E Safar

Abstract

We have previously shown that long-term angiotensin-converting enzyme (ACE) inhibition prevents the increase in aortic collagen in spontaneously hypertensive rats (SHRs), independent of blood pressure reduction. More recently, we reported that the effects of ACE inhibition in the prevention of aortic collagen accumulation were related to the inhibition of angiotensin II actions on angiotensin II type 1 receptors. Aldosterone, the synthesis of which is mainly modulated by angiotensin II through type 1 receptor stimulation, is known to promote cardiac fibrosis in different experimental models. The aim of the present study was to determine whether inhibition of aldosterone formation was able to prevent aortic fibrosis in SHRs. For this purpose, we compared the effects of a 4-month treatment with the aldosterone antagonist spironolactone with the ACE inhibitor quinapril in 4-week-old SHRs. Control SHRs and Wistar-Kyoto (WKY) rats received placebo for the same period of time. At the end of treatment, in conscious SHRs vs WKY controls, quinapril completely prevented the development of hypertension, whereas spironolactone produced only a slight but significant reduction in blood pressure. Aortic hypertrophy was significantly prevented...Continue Reading

References

Apr 1, 1992·British Journal of Pharmacology·W Linz, B A Schölkens
Jul 1, 1992·Cardiovascular Research·C G Brilla, K T Weber
Jan 1, 1990·Fundamental & Clinical Pharmacology·S LaurentM E Safar
Jan 1, 1989·Clinical and Experimental Hypertension. Part A, Theory and Practice·W LinzD Ganten
Jan 1, 1987·Journal of Steroid Biochemistry·M Worcel, A M Moura
Aug 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·A OoshimaS Udenfriend
Feb 1, 1982·Journal of Steroid Biochemistry·L KornelW J Raynor
Jul 1, 1994·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·A BenetosM E Safar
Jul 1, 1994·Journal of Molecular and Cellular Cardiology·C G BrillaK T Weber
Jun 1, 1994·The Journal of Clinical Investigation·M YoungJ Funder
Dec 1, 1967·The Journal of Physiology·M F Lockett

❮ Previous
Next ❯

Citations

Jul 11, 2000·Journal of Molecular and Cellular Cardiology·P Lijnen, V Petrov
Jan 24, 2007·Pflügers Archiv : European journal of physiology·Michael GekleClaudia Grossmann
Feb 15, 2011·Pflügers Archiv : European journal of physiology·Katrin KlicheHans Oberleithner
Sep 12, 2000·Current Hypertension Reports·D DuprezD L Clement
May 17, 2001·Current Hypertension Reports·S Rajagopalan, B Pitt
May 7, 2004·Current Hypertension Reports·William H Frishman, Charles T Stier
Sep 12, 2000·Current Hypertension Reports·A B Fogo
Sep 10, 2003·The Journal of Laboratory and Clinical Medicine·Karl T Weber
Feb 24, 2001·Journal of the American College of Cardiology·P LacolleyA Benetos
Nov 21, 2001·Current Opinion in Pharmacology·E G McMahon
Feb 13, 2001·Kidney International·A B Fogo
Feb 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Youngtae JeongCharles J Lowenstein
Jan 21, 2006·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Athanase BenetosAbraham Aviv
Apr 25, 2007·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Hyun Seok HwangMarvin O Boluyt
Mar 16, 2002·Cardiology in Review·Charles T StierRicardo Rocha
Jan 6, 2007·Journal of Cardiovascular Pharmacology·Micheline Monteiro de ResendeAndrew Seth Greene
Apr 12, 2005·Current Opinion in Nephrology and Hypertension·Nancy J Brown
Jan 9, 2009·Journal of Cardiovascular Pharmacology·Philip E BrandishJames C Hershey
Aug 10, 2011·Journal of Hypertension·Michel E SafarJacques Blacher
May 21, 2009·American Journal of Therapeutics·Matthew D BacchettaDaniel F Catanzaro
Aug 14, 2009·Clinical and Experimental Pharmacology & Physiology·Wei-Qing HanPing-Jin Gao
Jul 26, 2012·Oxidative Medicine and Cellular Longevity·Saeid GolbidiIsmail Laher
Mar 22, 2007·Kidney & Blood Pressure Research·Paul Gusbeth-Tatomir, Adrian Covic
Nov 23, 2012·Journal of Vascular Research·Marie Briet, Ernesto L Schiffrin
Jan 1, 2010·Integrated Blood Pressure Control·Francesca Kum, Janaka Karalliedde
Mar 5, 2013·American Journal of Physiology. Lung Cellular and Molecular Physiology·Ioana R PrestonIris Z Jaffe
Apr 27, 2001·Expert Opinion on Investigational Drugs·S A Doggrell, L Brown
Jul 15, 2015·American Journal of Hypertension·Harold SmulyanMichel E Safar
Dec 30, 2014·American Journal of Hypertension·Vanessa TzamouGregory Vyssoulis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.